35 results about "Complement factor B" patented technology

The invention provides a CR2-FH molecule comprising a CR2 portion comprising CR2 protein or a fragment thereof and a FH portion comprising a factor H protein or a fragment thereof, and pharmaceutical compositions comprising a CR2-FH molecule. Also provided are methods of using the compositions for treatment diseases in which the alternative complement pathway is implicated, such as age-related macular degeneration, rheumatoid arthritis, and ischemia reperfusion.

The invention provides a CR2-FH molecule comprising a CR2 portion comprising CR2 protein or a fragment thereof and a FH portion comprising a factor H protein or a fragment thereof, and pharmaceutical compositions comprising a CR2-FH molecule. Also provided are methods of using the compositions for treatment diseases in which the alternative complement pathway is implicated, such as age-related macular degeneration, rheumatoid arthritis, and ischemia reperfusion.

The present invention provides a compound of formula (I): wherein X is N or CH, Y is NH, O or S, methods for manufacturing these compounds, and their uses as Factor B inhibitors for the treatment of conditions and diseases associated with complement alternative pathway activation such as age-related macular degeneration, diabetic retinopathy and related ophthalmic diseases. The present invention further provides pharmaceutical compositions and combinations of pharmacologically active agents.

The invention relates to iRNA, e.g., double-stranded ribonucleic acid (dsRNA), compositions targeting the complement factor B (CFB) gene, the complement component C3 gene, and the complement component C9 gene and methods of using such iRNA, e.g., dsRNA, compositions to inhibit expression of CFB, C9 and / or C3 and to treat subjects having a complement component-associated disease, e.g., paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.

Assays for detection of bactericidal anti-Neisserial antibodies using a factor H polypeptide having a human amino acid sequence that mediates binding to Neisserial factor H binding protein (fhBp) are provided, as well as non-human animal models of Neisserial infection.

The invention provides polypeptides comprising a complement factor B analog. The invention also provides various complement factor B analogs including complement factor B analogs comprising a mutation of a free cysteine amino acid and related methods, nucleic acids and vectors. These complement factor B analogs and related methods, nucleic acids and vectors can be used to modulate a complement pathway or for the study and / or treatment of various conditions or diseases related to a complement pathway.

The present application relates to a kit for diagnosing pancreatic cancer, a method for providing information for diagnosing pancreatic cancer using the kit, and a method for diagnosing pancreatic cancer using same, wherein the kit includes an antibody specifically binding to complement factor B protein and an antibody specifically binding to carbohydrate antigen 19-9 protein. According to the present application, it is possible to provide a marker for diagnosing pancreatic cancer having enhanced sensitivity and specificity.

The invention relates to a preparation method of a yolk antibody IgY of high-abundance protein in anti-human serum / blood plasma and application thereof; and eggs of a hen immunized by high-abundance protein are used as a source for extracting antibody. The preparation method comprises the steps of: detecting the serum potency of the immunized hen through an indirect ELISA method, obtaining an eggcontaining antibody with high potency after the potency meets the standard; acid hydrolyzing, freeze thawing and filtering the egg yolk liquid, and depositing by using ammonium sulphate; and further purifying through DEAE ion exchange layer chromatograph to obtain the yolk antibody IgY. The high-abundance protein of human serum / blood plasma is a high-abundance protein with albumin, IgG, transferrin, C3 alexin, IgA, IgM, trypsin, globin, lipoprotein, F factor, C9 alexin, C4 alexin, ceruloplasmin, apolipoprotein B, apolipoprotein A-1, alpha-1-acid glycoprotein, H factor, alexin factor B, prealbumin and C1q alexin, and the like, and the concentration of which are higher than 10 mug / ml.

The invention provides a heterocyclic compound containing piperidine as shown in a formula (I). The compounds are used for treating diseases and diseases related to complement alternative pathway activation, such as paroxysmal nocturnal hemoglobinuria (PNH), IgA nephropathy (IgAN) including C3 glomerulopathy (C3G), membranous nephropathy (MN) and other glomerular diseases, atypical hemolytic uremic syndrome (aHUS), age-related macular degeneration (AMD), diabetic retinopathy (DR), and other diseases associated with abnormal activation of the alternative complement pathway by inhibiting / regulating a complement factor B.

The invention provides polypeptides comprising a complement factor B analog. The invention also provides various complement factor B analogs including complement factor B analogs comprising a mutation of a free cysteine amino acid and related methods, nucleic acids and vectors. These complement factor B analogs and related methods, nucleic acids and vectors can be used to modulate a complement pathway or for the study and / or treatment of various conditions or diseases related to a complement pathway.

The invention relates to a correlation between serum complement Factor H levels and binding to C-reactive protein (CRP) and risk of developing age-related macular degeneration. The invention provides methods for screening a subject to assess risk of developing AMD. The invention also provides methods for screening for agents useful to treat AMD.

Methods, compositions and kits for detecting the complement Factor B cleavage product Ba in a biological sample are described. These methods, compositions and kits are useful in convenient, reliable and early diagnosis of or ruling out pre-eclampsia in a pregnant human subject.

The present invention provides a method of identifying meningitis as either bacterial meningitis or aseptic meningitis in a subject, comprising: a) measuring the amount of complement C3, complement factor B, complement membrane attack complex (MAC) protein, complement C5b, complement C6, complement C7, complement C8, and / or complement C9 in a cerebrospinal fluid (CSF) sample obtained from the subject; and b) comparing the amount of complement C3, complement factor B, complement MAC protein, complement C5b, complement C6, complement C7, complement C8, and / or complement C9 measured in (a) with the amount of complement C3, complement factor B, complement MAC protein, complement C5b, complement C6, complement C7, complement C8, and / or complement C9 measured in a control sample, wherein an amount of complement C3, complement factor B, complement MAC protein, complement C5b, complement C6, complement C7, complement C8, and / or complement C9 measured in (a) that is greater than the amount of complement C3, complement factor B, complement MAC protein, complement C5b, complement C6, complement C7, complement C8, and / or complement C9 measured in the control sample identifies the meningitis in the subject as bacterial meningitis.

The invention relates to means and methods that relate to binding molecules that bind human complement factor C2. Specific binding molecules are described with specific C2 activity inhibiting properties. Such binding molecules are useful in the treatment of symptoms of various human diseases among which there is inflammatory disease, neuro-inflammatory disease or ischemia-reperfusion (I / R) injury. Disease.

The present invention provides a method of identifying meningitis as either bacterial meningitis or aseptic meningitis in a subject, comprising: a) measuring the amount of complement C3, complement factor B, complement membrane attack complex (MAC) protein, complement C5b, complement C6, complement C7, complement C8, and / or complement C9 in a cerebrospinal fluid (CSF) sample obtained from the subject; and b) comparing the amount of complement C3, complement factor B, complement MAC protein, complement C5b, complement C6, complement C7, complement C8, and / or complement C9 measured in (a) with the amount of complement C3, complement factor B, complement MAC protein, complement C5b, complement C6, complement C7, complement C8, and / or complement C9 measured in a control sample, wherein an amount of complement C3, complement factor B, complement MAC protein, complement C5b, complement C6, complement C7, complement C8, and / or complement C9 measured in (a) that is greater than the amount of complement C3, complement factor B, complement MAC protein, complement C5b, complement C6, complement C7, complement C8, and / or complement C9 measured in the control sample identifies the meningitis in the subject as bacterial meningitis.

The present invention relates to an assay for specific detection of complement factor H-related protein 1 (CFHR1) in a sample from a subject, as well as kits and agents related thereto.

The present disclosure belongs to the field of anti-tumor drugs and particularly relates to applications of a complement factor H (CFH) in preparing an anti-lung adenocarcinoma drug. Related studies in the prior art show that CFH mutations can lead to increases in retinal choroidal neovascularization. As a malignant tumor, growth and metastasis of lung adenocarcinoma have a close relationship withangiogenesis. The studies are developed aiming at a function of the CFH on the angiogenesis in a lung adenocarcinoma model. Results show that the number and volume of lesions are significantly reduced and neovascularization is inhibited after injection of CFH recombinant proteins in a mouse model of the lung adenocarcinoma, indicating a therapeutic effect of the lung adenocarcinoma. Aiming at anaction mechanism of the CFH, studies show that the CFH may inhibit migration of endothelial cells by inhibiting phosphorylation of p38 in the endothelial cells. The studies demonstrate that the CFH has the therapeutic effect on the lung adenocarcinoma and is expected to be developed as the anti-lung adenocarcinoma drug.

The invention relates to a urine protein marker for asthma and application thereof. The present application relates to the application of a urine protein marker selected from a group consisting of epidermal growth factor receptor substrate 15, Cathelicidin antimicrobial peptide, haptoglobin, alpha-1-acidic glycoprotein 1, prolactin-inducing protein homolog, odorant binding protein 2a, protein LEG1homolog, complement factor B, retinoid beta, beta-2 microglobulin, prothrombin, eosinophilic granulocyte cationic protein 1, protein AMBP, plasminogen, a procollagen C-endopeptidase enhancer 1, a sodium channel and gridding protein connecting agent 1 and vitamin D binding protein. According to the application, an animal model for screening the asthma-related urine protein marker is established, the asthma-related urine protein marker is obtained by using the established animal model, and an application of a detection reagent of the marker in preparation of a kit for diagnosing asthma of a subject is also established.

The invention relates to a preparation method of a yolk antibody IgY of high-abundance protein in anti-human serum / blood plasma and application thereof; and eggs of a hen immunized by high-abundance protein are used as a source for extracting antibody. The preparation method comprises the steps of: detecting the serum potency of the immunized hen through an indirect ELISA method, obtaining an egg containing antibody with high potency after the potency meets the standard; acid hydrolyzing, freeze thawing and filtering the egg yolk liquid, and depositing by using ammonium sulphate; and further purifying through DEAE ion exchange layer chromatograph to obtain the yolk antibody IgY. The high-abundance protein of human serum / blood plasma is a high-abundance protein with albumin, IgG, transferrin, C3 alexin, IgA, IgM, trypsin, globin, lipoprotein, F factor, C9 alexin, C4 alexin, ceruloplasmin, apolipoprotein B, apolipoprotein A-1, alpha-1-acid glycoprotein, H factor, alexin factor B, prealbumin and C1q alexin, and the like, and the concentration of which are higher than 10 mug / ml.